Digest Network Come funziona
Network
/
Società
Al
Non verificato

Alnylam Pharmaceuticals, Inc.

Di cosa scriviamo

BiotecnologiaFarmaceuticaMedicina - VarieSaluteWeb e Social Network

71 comunicati stampa

Guarda tutti i comunicati
12/06/2026
Web e Social Network
Eventi
Biotecnologia
Salute
Scienza
Farmaceutica
Alnylam to Host Tenth “RNAi Roundtable” Webcast Series
Fonte
Alnylam Pharmaceuticals, Inc.
Emittente
Business Wire
1.00
0
19/05/2026
Information Technology
Associazioni/Professionisti
Scienza
Tecnica
Sanità
Farmaceutica
Ecologia/Salute ambientale
Biotecnologia
Tecnologie Varie
Salute
Industria
Alnylam Issues 2025 Corporate Responsibility Report
Fonte
Alnylam Pharmaceuticals, Inc.
Emittente
Business Wire
1.00
0
12/05/2026
Eventi
Industria
Salute
Biotecnologia
Medicina - Varie
Farmaceutica
Cardiologia
New Data Analyses Presented at Heart Failure 2026 Demonstrate Robust and Consistent Clinical Benefit of Vutrisiran as a First-Line Treatment Option Across ATTR-CM Patient Populations, Including Patients with a High Disease Burden
Fonte
Alnylam Pharmaceuticals, Inc.
Emittente
Business Wire
1.00
0
07/05/2026
Web e Social Network
Eventi
Industria
Salute
Scienza
Farmaceutica
Biotecnologia
Alnylam to Webcast Presentations at Upcoming Investor Conferences
Fonte
Alnylam Pharmaceuticals, Inc.
Emittente
Business Wire
1.00
0
04/05/2026
Eventi
Industria
Cardiologia
Biotecnologia
Sanità
Salute
Farmaceutica
Scienza
Medicina - Varie
Alnylam to Present New Analyses at Heart Failure 2026 Underscoring Consistent Clinical Profile of Vutrisiran in ATTR-CM
Fonte
Alnylam Pharmaceuticals, Inc.
Emittente
Business Wire
1.00
0
30/04/2026
Web e Social Network
Telefonia e Varie
Mercato azionario
Biotecnologia
Sanità
Farmaceutica
Salute
Alnylam Pharmaceuticals Reports First Quarter 2026 Financial Results and Highlights Recent Period Progress
Fonte
Alnylam Pharmaceuticals, Inc.
Emittente
Business Wire
1.00
0
16/04/2026
Web e Social Network
Telefonia e Varie
Finanza
Mercato azionario
Biotecnologia
Farmaceutica
Salute
Alnylam to Webcast Conference Call Discussing First Quarter 2026 Financial Results
Fonte
Alnylam Pharmaceuticals, Inc.
Emittente
Business Wire
1.00
0
30/03/2026
Eventi
Industria
Salute
Biotecnologia
Medicina - Varie
Farmaceutica
Cardiologia
New Data Presented at ACC.26 Further Support Benefits of Vutrisiran in ATTR-CM and Potential of Zilebesiran for Hypertension Management
Fonte
Alnylam Pharmaceuticals, Inc.
Emittente
Business Wire
1.00
0
24/03/2026
Web e Social Network
Mercato del lavoro
Industria
Tecnica
Biotecnologia
Cardiologia
Sanità
Salute
Farmaceutica
Alnylam Advances Future of ATTR-CM Care Through Strategic Collaboration with Viz.ai and Support for the American Heart Association
Fonte
Alnylam Pharmaceuticals, Inc.
Emittente
Business Wire
1.00
0
10/03/2026
Finanza
Web e Social Network
Biotecnologia
Farmaceutica
Salute
Alnylam to Webcast TTR Investor Webinar
Fonte
Alnylam Pharmaceuticals, Inc.
Emittente
Business Wire
1.00
0

Recapiti

Social Media

Seguaci
0
Compatibilità
0